RU2146256C1 - ПРОИЗВОДНЫЕ АЗОЛА И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ С АКТИВНОСТЬЮ В ОТНОШЕНИИ СЕРОТОНИНОВОГО (5-HT1Dα)РЕЦЕПТОРА - Google Patents

ПРОИЗВОДНЫЕ АЗОЛА И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ С АКТИВНОСТЬЮ В ОТНОШЕНИИ СЕРОТОНИНОВОГО (5-HT1Dα)РЕЦЕПТОРА Download PDF

Info

Publication number
RU2146256C1
RU2146256C1 RU95115522A RU95115522A RU2146256C1 RU 2146256 C1 RU2146256 C1 RU 2146256C1 RU 95115522 A RU95115522 A RU 95115522A RU 95115522 A RU95115522 A RU 95115522A RU 2146256 C1 RU2146256 C1 RU 2146256C1
Authority
RU
Russia
Prior art keywords
alkyl
mmol
mixture
tetrahydro
pyrido
Prior art date
Application number
RU95115522A
Other languages
English (en)
Russian (ru)
Other versions
RU95115522A (ru
Inventor
Джилмор Джереми
Таддеуш Галлагер Питер
Виктор Майлз Мартин
Мартин Оутон Вилльям
Вилльям Смит Колин
Original Assignee
Лилли Индастриз Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9418326A external-priority patent/GB9418326D0/en
Priority claimed from GBGB9511166.2A external-priority patent/GB9511166D0/en
Application filed by Лилли Индастриз Лимитед filed Critical Лилли Индастриз Лимитед
Publication of RU95115522A publication Critical patent/RU95115522A/ru
Application granted granted Critical
Publication of RU2146256C1 publication Critical patent/RU2146256C1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Holo Graphy (AREA)
RU95115522A 1994-09-12 1995-09-11 ПРОИЗВОДНЫЕ АЗОЛА И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ С АКТИВНОСТЬЮ В ОТНОШЕНИИ СЕРОТОНИНОВОГО (5-HT1Dα)РЕЦЕПТОРА RU2146256C1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9418326.6 1994-09-12
GB9418326A GB9418326D0 (en) 1994-09-12 1994-09-12 Pharmaceutical compounds
GBGB9511166.2A GB9511166D0 (en) 1995-06-02 1995-06-02 Pharmaceutical compounds
GB9511166.2 1995-06-02

Publications (2)

Publication Number Publication Date
RU95115522A RU95115522A (ru) 1997-08-27
RU2146256C1 true RU2146256C1 (ru) 2000-03-10

Family

ID=26305611

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95115522A RU2146256C1 (ru) 1994-09-12 1995-09-11 ПРОИЗВОДНЫЕ АЗОЛА И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ С АКТИВНОСТЬЮ В ОТНОШЕНИИ СЕРОТОНИНОВОГО (5-HT1Dα)РЕЦЕПТОРА

Country Status (22)

Country Link
EP (1) EP0705832B1 (enExample)
JP (1) JPH0881464A (enExample)
KR (1) KR960010635A (enExample)
CN (1) CN1045602C (enExample)
AT (1) ATE247114T1 (enExample)
AU (1) AU698580B2 (enExample)
CA (1) CA2157998A1 (enExample)
CZ (1) CZ286565B6 (enExample)
DE (1) DE69531476T2 (enExample)
ES (1) ES2204932T3 (enExample)
FI (1) FI954243A7 (enExample)
HU (1) HU219491B (enExample)
IL (1) IL115236A (enExample)
IN (1) IN179550B (enExample)
MY (1) MY132009A (enExample)
NO (1) NO305174B1 (enExample)
NZ (1) NZ272961A (enExample)
PE (1) PE41796A1 (enExample)
PH (1) PH31631A (enExample)
PL (1) PL310373A1 (enExample)
RU (1) RU2146256C1 (enExample)
TR (1) TR199501114A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2232578C1 (ru) * 2003-04-10 2004-07-20 Ахапкина Валентина Ивановна Вещество, обладающее антидепрессивной активностью
RU2745742C1 (ru) * 2015-10-01 2021-03-31 Олема Фармасьютикалз, Инк. ТЕТРАГИДРО-1Н-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2308362A (en) * 1995-12-19 1997-06-25 Lilly Industries Ltd Pharmaceutical indole derivatives
EP0905136A1 (en) * 1997-09-08 1999-03-31 Janssen Pharmaceutica N.V. Tetrahydro gamma-carbolines
UA70334C2 (en) * 1998-10-06 2004-10-15 Janssen Pharmaceutica N V Jans BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS
UA74826C2 (en) * 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
AU7887501A (en) * 2000-07-06 2002-01-21 Us Gov Health & Human Serv Tetrahydrobenzothiazole analogues as neuroprotective agents
DE10040016A1 (de) * 2000-08-16 2002-02-28 Boehringer Ingelheim Pharma Neue beta-Amyloid Inhibitoren, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
AU2002223528A1 (en) * 2000-09-19 2002-04-02 Boeringer Ingelheim Pharma Gmbh & Co. Kg New n, n'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
US6586435B2 (en) 2000-09-19 2003-07-01 Boehringer Ingelheim Pharma Kg Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
WO2002024662A1 (en) * 2000-09-19 2002-03-28 Boehringer Ingelheim Pharma Gmbh & Ko. Kg New benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
WO2003014118A1 (en) * 2001-08-08 2003-02-20 Pharmacia & Upjohn Company THERAPEUTIC 1H-PYRIDO[4,3-b]INDOLES
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
EP1945214A1 (en) 2005-10-29 2008-07-23 Boehringer Ingelheim International GmbH Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20090312242A1 (en) 2006-06-30 2009-12-17 Ramiro Castro Flibanserin for the treatment of urinary incontinence and related diseases
AR062320A1 (es) 2006-08-14 2008-10-29 Boehringer Ingelheim Int Formulaciones de flibanserina y metodo para fabricarlas
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
CN104721168A (zh) 2006-08-25 2015-06-24 贝林格尔·英格海姆国际有限公司 控制释放系统及其制造方法
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
CA2762620A1 (en) 2009-05-29 2010-12-02 Sumitomo Chemical Company, Limited Agent for treatment or prevention of diseases associated with activity of neurotrophic factors
AU2020311337A1 (en) 2019-07-07 2022-01-20 Olema Pharmaceuticals, Inc. Regimens of estrogen receptor antagonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1442074A3 (ru) * 1985-09-16 1988-11-30 Американ Хоум Продактс Корпорейшн (Фирма) Способ получени производных @ -карболина или их фармацевтически приемлемых солей

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4035369A (en) 1975-10-08 1977-07-12 Janssen Pharmaceutica N.V. 1-Benzazolylalkyl-4-substituted-piperidines
IL69132A (en) * 1982-07-14 1986-02-28 Roussel Uclaf Benzo-and naphtho-thiopyranopyrimidinones,their preparation and pharmaceutical compositions containing them
FR2661177A1 (fr) * 1990-04-23 1991-10-25 Rhone Poulenc Sante Derives du naphtosultame antagonistes de la serotonine, leur preparation et les medicaments les contenant.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1442074A3 (ru) * 1985-09-16 1988-11-30 Американ Хоум Продактс Корпорейшн (Фирма) Способ получени производных @ -карболина или их фармацевтически приемлемых солей

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2232578C1 (ru) * 2003-04-10 2004-07-20 Ахапкина Валентина Ивановна Вещество, обладающее антидепрессивной активностью
RU2745742C1 (ru) * 2015-10-01 2021-03-31 Олема Фармасьютикалз, Инк. ТЕТРАГИДРО-1Н-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА
US11229630B2 (en) 2015-10-01 2022-01-25 Olema Pharmaceuticals, Inc. Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs
US11672785B2 (en) 2015-10-01 2023-06-13 Olema Pharmaceuticals, Inc. Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs

Also Published As

Publication number Publication date
TR199501114A2 (tr) 1996-10-21
ATE247114T1 (de) 2003-08-15
IL115236A (en) 1998-06-15
IL115236A0 (en) 1995-12-31
DE69531476D1 (de) 2003-09-18
CN1129219A (zh) 1996-08-21
HUT72593A (en) 1996-05-28
NO953575D0 (no) 1995-09-11
KR960010635A (ko) 1996-04-20
EP0705832A1 (en) 1996-04-10
NO305174B1 (no) 1999-04-12
HU219491B (hu) 2001-04-28
IN179550B (enExample) 1997-10-18
PH31631A (en) 1999-01-12
MY132009A (en) 2007-09-28
CZ286565B6 (cs) 2000-05-17
EP0705832B1 (en) 2003-08-13
FI954243A7 (fi) 1996-03-13
NZ272961A (en) 1998-02-26
PL310373A1 (en) 1996-03-18
FI954243A0 (fi) 1995-09-11
AU698580B2 (en) 1998-11-05
NO953575L (no) 1996-03-13
PE41796A1 (es) 1996-10-21
CN1045602C (zh) 1999-10-13
CZ232295A3 (en) 1996-03-13
DE69531476T2 (de) 2004-06-09
CA2157998A1 (en) 1996-03-13
ES2204932T3 (es) 2004-05-01
HU9502631D0 (en) 1995-11-28
JPH0881464A (ja) 1996-03-26
AU3049795A (en) 1996-03-28

Similar Documents

Publication Publication Date Title
RU2146256C1 (ru) ПРОИЗВОДНЫЕ АЗОЛА И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ С АКТИВНОСТЬЮ В ОТНОШЕНИИ СЕРОТОНИНОВОГО (5-HT1Dα)РЕЦЕПТОРА
DK174161B1 (da) Anellerede indolderivater, fremgangsmåde til deres fremstilling og fremgangsmåde til fremstilling af farmaceutisk præparat indeholdende dem
AU702548B2 (en) Chemical compounds
EP0666858B1 (en) 5-arylindole derivatives and their use as serotonin (5-ht 1) agonists
AU671836B2 (en) Fused imidazole and triazole derivatives as 5-HT1 receptor agonists
EP0397060A2 (de) Maleinimid-Derivate und deren Verwendung als Arzneimittel
JPH06279442A (ja) ピロロ−ピリジン誘導体
US5563147A (en) Serotonerbic tetrahydropyridoindoles
CN110023291A (zh) 三环rho激酶抑制剂
NZ264596A (en) Imidazol-4-ylpiperidines; compounds, preparation and pharmaceutical compositions containing them
EP0730593A1 (en) Morpholine derivatives as dopamine receptor subtype ligands
WO2001032660A1 (en) Compounds having 5-ht6 receptor antagonist activity
PL210413B1 (pl) Pochodne indoliloalkiloaminy
AU779832B2 (en) Azaindoles having serotonin receptor affinity
MXPA06007654A (es) Derivados de piperidina n-sustituidos.
RS63671B1 (sr) Supstitutisani derivati triazolo hinoksalina
DD297970A5 (de) Verfahren zur herstellung von be1-(1h-indol-3-yl)-maleinimid-derivaten und deren verwendung
RS51605B (sr) 3-fenil supstituisani piridoindolon, njegova izrada i terapeutska upotreba
WO2015012704A1 (en) Pyrroloquinoline derivatives as 5-ht6 antagonists, preparation method and use thereof
JPH09502449A (ja) ドーパミン受容体サブタイプリガンドとしての縮合三環複素芳香族誘導体
FI83220B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 1,3-dimetyl-1h-purin-2,6-dionderivat.
US6897215B1 (en) Compounds having 5-HT6 receptor antagonist activity
FR2868422A1 (fr) Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
TW589312B (en) Aryl-8-azabicyclo[3.2.1]octanes for the treatment of depression
EA001469B1 (ru) Замещенные 4-(6-фтор-(1н)-индол-3-ил)-1,2,3,6-тетрагидропиридин для лечения нарушений центральной нервной системы